Cellectis (NASDAQ:CLLS - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "hold" rating in a note issued to investors on Saturday.
Cellectis Trading Up 5.5%
CLLS traded up $0.19 during trading on Friday, hitting $3.63. The company's stock had a trading volume of 116,370 shares, compared to its average volume of 211,928. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.76. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.58. The stock's fifty day moving average price is $2.65 and its 200-day moving average price is $1.85. The firm has a market capitalization of $201.76 million, a P/E ratio of -4.43 and a beta of 3.03.
Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $18.19 million during the quarter, compared to the consensus estimate of $10.07 million. Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. Analysts anticipate that Cellectis will post -0.46 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in CLLS. OLD Mission Capital LLC bought a new stake in shares of Cellectis in the 1st quarter worth approximately $31,000. Acadian Asset Management LLC increased its holdings in shares of Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after buying an additional 26,461 shares during the period. Long Focus Capital Management LLC lifted its holdings in shares of Cellectis by 2.2% during the first quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after purchasing an additional 100,000 shares in the last quarter. Millennium Management LLC bought a new position in shares of Cellectis during the fourth quarter valued at $962,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock valued at $5,856,000 after acquiring an additional 3,284,409 shares during the last quarter. Institutional investors own 63.90% of the company's stock.
Cellectis Company Profile
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.